NCT04147195 - Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

January 6, 2022

Study Completion Date

January 6, 2022

Conditions

Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis

Interventions

DRUG

LYS006

5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks

DRUG

Tropifexor

100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks

Trial Locations (10)

Novartis Investigative Site, Morehead City

Novartis Investigative Site, Marietta

Novartis Investigative Site, Miami Lakes

Novartis Investigative Site, Essen

Novartis Investigative Site, South Bend

Novartis Investigative Site, San Antonio

Novartis Investigative Site, Los Angeles

Novartis Investigative Site, Coronado

Novartis Investigative Site, Honolulu

Novartis Investigative Site, Buenos Aires